PleoPharma Inc., a private company focused on treating cannabis-related health issues, closed a $36M Series B financing round to advance its lead asset, PP-01, which is an investigational product for treating cannabis use disorder. SuperVision Partners LLC and Castle Hill Capital Partners Inc. served as placement agents.

PleoPharma Closes $36M Series B Financing Round

Oct 21, 2025

Source:

Mg Magazine Newswire

MG Magazine

*PHOENIXVILLE, Pa.* — PleoPharma Inc., a privately held company focused on
finding treatments for cannabis-related health issues, closed a $36M Series
B financing round.

PleoPharma will use the proceeds to advance its lead asset, PP-01, an
investigational product for treating cannabis use disorder.

SuperVision Partners LLC served as the lead placement agent for the
offering along with Castle Hill Capital Partners Inc.

Recent Reviews

Fade Co.’s Boston Tea Party: A Declaration of Independence from Boring Vapes

As we stand on the eve of the Fourth of July, what better way to celebrate American independence than with a strain literally named after the spark that lit the fuse? Fade Co.’s Boston Tea Party All-in-One live resin disposable is currently available at Story Dispensary locations across Maryland (including Waldorf), and it feels like a cheeky act of defiance against boring vapes everywhere...

Cookies BernieHana Butter & Tequila Sunrise Dual Chamber Terp Vape - Takoma Wellness Center

This Dual Chamber 3-in-1 Cookies cannabis terp vape, currently available at Takoma Wellness Center, introduces an intriguing level of cho...

RHYTHM Cannabis' Afternoon Delight 4 Strain Review

I was excited to try one of the newest drops from RHYTHM, Afternoon Delight 4 and I knew that first impressions were going to mean everything. With this being a GMO cross, I was already expecting some funk, but I was pleasantly surprised with how many other notes were present...

2 3 4 5

Menu